J. Goldman & CO LP Apellis Pharmaceuticals, Inc. Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $6.33 Million - $7.7 Million	-82,549 Reduced 90.69%	8,476 $772,000
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $4.24 Million - $6.1 Million	91,025 New	91,025 $6 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $1.42 Million - $2.39 Million	-40,377 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $270,772 - $413,260	-7,636 Reduced 15.9%	40,377 $2.05 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $1.48 Million - $2.36 Million	48,013 New	48,013 $2.27 Million

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.